Carcinoembryonic antigen (CEA) is still the most valuable tumor marker in the diagnosis and prognosis of non-small cell lung cancer (NSCLC) patients; however, its application is largely limited by its low sensitivity in stage I cases. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.